MedTrace Logo

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

NCT03335540 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-09-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the treatment of solid tumors with various immunotherapy combinations. The treatment will be determined based upon a broad biomarker assessment.

Conditions

Interventions

BIOLOGICAL

Nivolumab

Specified dose on specified day

BIOLOGICAL

Relatlimab

Specified dose on specified day

BIOLOGICAL

Cabiralizumab

Specified dose on specified day

BIOLOGICAL

Ipilimumab

Specified dose on specified day

DRUG

IDO1 Inhibitor

Specified dose on specified day

RADIATION

Radiation Therapy

Specified dose on specified day

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-07
Primary Completion
2021-03-31
Completion
2021-08-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03335540 on ClinicalTrials.gov